{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:19:25Z","timestamp":1793679565239,"version":"4.5.1"},"reference-count":192,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41573-026-01426-2","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T08:28:52Z","timestamp":1776673732000},"page":"648-662","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety considerations for cereblon-recruiting targeted protein degraders"],"prefix":"10.1038","volume":"25","author":[{"given":"Helen","family":"Garside","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Aslamkhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7659-3020","authenticated-orcid":false,"given":"Danette L.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushik","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5258-2442","authenticated-orcid":false,"given":"Mikael","family":"Egebjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0348-7585","authenticated-orcid":false,"given":"Renee R.","family":"Hukkanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8388-5865","authenticated-orcid":false,"given":"Lyn H.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Ketter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejas S.","family":"Lahoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise I.","family":"Loberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davorka","family":"Messmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raegan","family":"O\u2019Lone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Pastoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Pavkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5836-6011","authenticated-orcid":false,"given":"Lucilia","family":"Pereira Mouri\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoran","family":"Rankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Rengarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8027-114X","authenticated-orcid":false,"given":"Neil","family":"Vargesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Vicart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9593-3572","authenticated-orcid":false,"given":"Ronald L.","family":"Wange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Yanochko-Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7763-7558","authenticated-orcid":false,"given":"Ruth","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Sidaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"1426_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1126\/science.1177319","volume":"327","author":"T Ito","year":"2010","unstructured":"Ito, T. et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345\u20131350 (2010).","journal-title":"Science"},{"key":"1426_CR2","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu, G. et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343, 305\u2013309 (2014).","journal-title":"Science"},{"key":"1426_CR3","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kr\u00f6nke","year":"2014","unstructured":"Kr\u00f6nke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301\u2013305 (2014).","journal-title":"Science"},{"key":"1426_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.66","volume":"5","author":"CC Bjorklund","year":"2015","unstructured":"Bjorklund, C. C. et al. Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. Blood Cancer J. 5, e354 (2015).","journal-title":"Blood Cancer J."},{"key":"1426_CR5","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/s41589-018-0129-x","volume":"14","author":"ME Matyskiela","year":"2018","unstructured":"Matyskiela, M. E. et al. SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate. Nat. Chem. Biol. 14, 981\u2013987 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"1426_CR6","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.38430","volume":"7","author":"KA Donovan","year":"2018","unstructured":"Donovan, K. A. et al. Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. eLife 7, e38430 (2018).","journal-title":"eLife"},{"key":"1426_CR7","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1021\/acs.biochem.2c00245","volume":"62","author":"JM Sasso","year":"2023","unstructured":"Sasso, J. M. et al. Molecular glues: the adhesive connecting targeted protein degradation to the clinic. Biochemistry 62, 601\u2013623 (2023).","journal-title":"Biochemistry"},{"key":"1426_CR8","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1056\/NEJM196212132672407","volume":"267","author":"GW Mellin","year":"1962","unstructured":"Mellin, G. W. & Katzenstein, M. The saga of thalidomide \u2014 neuropathy to embryopathy, with case reports of congenital anomalies. N. Engl. J. Med. 267, 1238\u20131244 (1962).","journal-title":"N. Engl. J. Med."},{"key":"1426_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1177\/1753193418805249","volume":"44","author":"N Vargesson","year":"2019","unstructured":"Vargesson, N. The teratogenic effects of thalidomide on limbs. J. Hand Surg. Eur. Vol. 44, 88\u201395 (2019).","journal-title":"J. Hand Surg. Eur. Vol."},{"key":"1426_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nature16979","volume":"532","author":"G Petzold","year":"2016","unstructured":"Petzold, G., Fischer, E. S. & Thom\u00e4, N. H. Structural basis of lenalidomide-induced CK1\u03b1 degradation by the CRL4CRBN ubiquitin ligase. Nature 532, 127\u2013130 (2016).","journal-title":"Nature"},{"key":"1426_CR11","doi-asserted-by":"publisher","first-page":"23106","DOI":"10.1073\/pnas.1917701117","volume":"117","author":"Y Hirose","year":"2020","unstructured":"Hirose, Y. et al. Hypnotic effect of thalidomide is independent of teratogenic ubiquitin\/proteasome pathway. Proc. Natl Acad. Sci. USA 117, 23106\u201323112 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1426_CR12","doi-asserted-by":"publisher","first-page":"11395","DOI":"10.1096\/fj.201903060RR","volume":"34","author":"SL Beedie","year":"2020","unstructured":"Beedie, S. L. et al. Role of cereblon in angiogenesis and in mediating the antiangiogenic activity of immunomodulatory drugs. FASEB J. 34, 11395\u201311404 (2020).","journal-title":"FASEB J."},{"key":"1426_CR13","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/intimm\/dxw005","volume":"28","author":"D Millrine","year":"2016","unstructured":"Millrine, D. et al. Immunomodulatory drugs inhibit TLR4-induced type-1 interferon production independently of Cereblon via suppression of the TRIF\/IRF3 pathway. Int. Immunol. 28, 307\u2013315 (2016).","journal-title":"Int. Immunol."},{"key":"1426_CR14","doi-asserted-by":"publisher","first-page":"11802","DOI":"10.1073\/pnas.1814446115","volume":"115","author":"Y Gemechu","year":"2018","unstructured":"Gemechu, Y. et al. Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs. Proc. Natl Acad. Sci. USA 115, 11802\u201311807 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1426_CR15","doi-asserted-by":"publisher","first-page":"5683","DOI":"10.3390\/molecules25235683","volume":"25","author":"ML Peach","year":"2020","unstructured":"Peach, M. L. et al. Antiangiogenic activity and in silico cereblon binding analysis of novel thalidomide analogs. Molecules 25, 5683 (2020).","journal-title":"Molecules"},{"key":"1426_CR16","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ydbio.2025.03.014","volume":"522","author":"LR Fraga","year":"2025","unstructured":"Fraga, L. R., Reeves, J., Mahony, C., Erskine, L. & Vargesson, N. Cereblon E3 ligase complex genes are expressed in tissues sensitive to thalidomide in chicken and zebrafish embryos but are unchanged following thalidomide exposure. Dev. Biol. 522, 156\u2013170 (2025).","journal-title":"Dev. Biol."},{"key":"1426_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/d41573-022-00055-9","volume":"21","author":"LH Jones","year":"2022","unstructured":"Jones, L. H. et al. Targeted protein degraders: a call for collective action to advance safety assessment. Nat. Rev. Drug Discov. 21, 401\u2013402 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1426_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-4-220","volume":"12","author":"A Sarikas","year":"2011","unstructured":"Sarikas, A., Hartmann, T. & Pan, Z.-Q. The cullin protein family. Genome Biol. 12, 220 (2011).","journal-title":"Genome Biol."},{"key":"1426_CR19","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1042\/BCJ20160762","volume":"474","author":"I Collins","year":"2017","unstructured":"Collins, I., Wang, H., Caldwell, J. J. & Chopra, R. Chemical approaches to targeted protein degradation through modulation of the ubiquitin\u2013proteasome pathway. Biochem. J. 474, 1127\u20131147 (2017).","journal-title":"Biochem. J."},{"key":"1426_CR20","doi-asserted-by":"publisher","first-page":"9130608","DOI":"10.1155\/2017\/9130608","volume":"2017","author":"Q Shi","year":"2017","unstructured":"Shi, Q. & Chen, L. Cereblon: a protein crucial to the multiple functions of immunomodulatory drugs as well as cell metabolism and disease generation. J. Immunol. Res. 2017, 9130608 (2017).","journal-title":"J. Immunol. Res."},{"key":"1426_CR21","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.bbamcr.2011.01.005","volume":"1813","author":"KM Lee","year":"2011","unstructured":"Lee, K. M., Jo, S., Kim, H., Lee, J. & Park, C.-S. Functional modulation of AMP-activated protein kinase by cereblon. Biochim. Biophys. Acta Mol. Cell Res. 1813, 448\u2013455 (2011).","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"1426_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2020.118729","volume":"1867","author":"S-J Yang","year":"2020","unstructured":"Yang, S.-J. et al. Ubiquitin-dependent proteasomal degradation of AMPK gamma subunit by Cereblon inhibits AMPK activity. Biochim. Biophys. Acta Mol. Cell Res. 1867, 118729 (2020).","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"1426_CR23","doi-asserted-by":"publisher","first-page":"9094","DOI":"10.3390\/ijms23169094","volume":"23","author":"J Cho","year":"2022","unstructured":"Cho, J. et al. UDP-glucose: a cereblon-dependent glucokinase protein degrader. Int. J. Mol. Sci. 23, 9094 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1426_CR24","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/j.1471-4159.2005.03344.x","volume":"94","author":"S Jo","year":"2005","unstructured":"Jo, S., Lee, K.-H., Song, S., Jung, Y.-K. & Park, C.-S. Identification and functional characterization of cereblon as a binding protein for large-conductance calcium-activated potassium channel in rat brain. J. Neurochem. 94, 1212\u20131224 (2005).","journal-title":"J. Neurochem."},{"key":"1426_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4924","volume":"5","author":"J Liu","year":"2014","unstructured":"Liu, J. et al. CRL4ACRBN E3 ubiquitin ligase restricts BK channel activity and prevents epileptogenesis. Nat. Commun. 5, 3924 (2014).","journal-title":"Nat. Commun."},{"key":"1426_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/srep10667","volume":"5","author":"Y-A Chen","year":"2015","unstructured":"Chen, Y.-A. et al. The cullin 4A\/B-DDB1-cereblon E3 ubiquitin ligase complex mediates the degradation of CLC-1 chloride channels. Sci. Rep. 5, 10667 (2015).","journal-title":"Sci. Rep."},{"key":"1426_CR27","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.3390\/cells9061332","volume":"9","author":"S-J Fu","year":"2020","unstructured":"Fu, S.-J. et al. CUL4-DDB1-CRBN E3 ubiquitin ligase regulates proteostasis of ClC-2 chloride channels: implication for aldosteronism and leukodystrophy. Cells 9, 1332 (2020).","journal-title":"Cells"},{"key":"1426_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19272-0","volume":"11","author":"H Moon","year":"2020","unstructured":"Moon, H. et al. Crbn modulates calcium influx by regulating Orai1 during efferocytosis. Nat. Commun. 11, 5489 (2020).","journal-title":"Nat. Commun."},{"key":"1426_CR29","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/nm.4128","volume":"22","author":"R Eichner","year":"2016","unstructured":"Eichner, R. et al. Immunomodulatory drugs disrupt the cereblon\u2013CD147\u2013MCT1 axis to exert antitumor activity and teratogenicity. Nat. Med. 22, 735\u2013743 (2016).","journal-title":"Nat. Med."},{"key":"1426_CR30","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.molcel.2020.12.046","volume":"81","author":"M Heider","year":"2021","unstructured":"Heider, M. et al. The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma. Mol. Cell 81, 1170\u20131186.e10 (2021).","journal-title":"Mol. Cell"},{"key":"1426_CR31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature13527","volume":"512","author":"ES Fischer","year":"2014","unstructured":"Fischer, E. S. et al. Structure of the DDB1\u2013CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 512, 49\u201353 (2014).","journal-title":"Nature"},{"key":"1426_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25634-z","volume":"12","author":"C Shen","year":"2021","unstructured":"Shen, C. et al. The E3 ubiquitin ligase component, cereblon, is an evolutionarily conserved regulator of Wnt signaling. Nat. Commun. 12, 5263 (2021).","journal-title":"Nat. Commun."},{"key":"1426_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.226","volume":"7","author":"Y Min","year":"2016","unstructured":"Min, Y. et al. Cereblon negatively regulates TLR4 signaling through the attenuation of ubiquitination of TRAF6. Cell Death Dis. 7, e2313 (2016).","journal-title":"Cell Death Dis."},{"key":"1426_CR34","doi-asserted-by":"publisher","first-page":"10141","DOI":"10.1074\/jbc.RA118.002246","volume":"293","author":"J Yang","year":"2018","unstructured":"Yang, J. et al. Cereblon suppresses the lipopolysaccharide-induced inflammatory response by promoting the ubiquitination and degradation of c-Jun. J. Biol. Chem. 293, 10141\u201310157 (2018).","journal-title":"J. Biol. Chem."},{"key":"1426_CR35","doi-asserted-by":"publisher","first-page":"8771","DOI":"10.1073\/pnas.1502166113","volume":"113","author":"J-A Kang","year":"2016","unstructured":"Kang, J.-A. et al. Epigenetic regulation of Kcna3-encoding Kv1.3 potassium channel by cereblon contributes to regulation of CD4+ T-cell activation. Proc. Natl Acad. Sci. USA 113, 8771\u20138776 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1426_CR36","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3390\/ph14060512","volume":"14","author":"S-J Yang","year":"2021","unstructured":"Yang, S.-J., Jeon, S., Baek, J. W., Lee, K. M. & Park, C.-S. Regulation of AMPK activity by CRBN is independent of the thalidomide-CRL4CRBN protein degradation axis. Pharmaceuticals 14, 512 (2021).","journal-title":"Pharmaceuticals"},{"key":"1426_CR37","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.molcel.2016.02.032","volume":"61","author":"T Van Nguyen","year":"2016","unstructured":"Van Nguyen, T. et al. Glutamine triggers acetylation-dependent degradation of glutamine synthetase via the thalidomide receptor cereblon. Mol. Cell 61, 809\u2013820 (2016).","journal-title":"Mol. Cell"},{"key":"1426_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-36367-3","volume":"8","author":"T-Y Choi","year":"2018","unstructured":"Choi, T.-Y. et al. BK channel blocker paxilline attenuates thalidomide-caused synaptic and cognitive dysfunctions in mice. Sci. Rep. 8, 17653 (2018).","journal-title":"Sci. Rep."},{"key":"1426_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2331-0","volume":"16","author":"Q Xu","year":"2016","unstructured":"Xu, Q. et al. Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival. BMC Cancer 16, 297 (2016).","journal-title":"BMC Cancer"},{"key":"1426_CR40","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41586-022-05333-5","volume":"610","author":"S Ichikawa","year":"2022","unstructured":"Ichikawa, S. et al. The E3 ligase adapter cereblon targets the C-terminal cyclic imide degron. Nature 610, 775\u2013782 (2022).","journal-title":"Nature"},{"key":"1426_CR41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2415976121","volume":"122","author":"W Xu","year":"2025","unstructured":"Xu, W. et al. Genesis and regulation of C-terminal cyclic imides from protein damage. Proc. Natl Acad. Sci. USA 122, e2415976121 (2025).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1426_CR42","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.chembiol.2024.01.003","volume":"31","author":"S Ichikawa","year":"2024","unstructured":"Ichikawa, S. et al. The cyclimids: degron-inspired cereblon binders for targeted protein degradation. Cell Chem. Biol. 31, 1162\u20131175.e10 (2024).","journal-title":"Cell Chem. Biol."},{"key":"1426_CR43","doi-asserted-by":"publisher","first-page":"17209","DOI":"10.1074\/jbc.M116.733626","volume":"291","author":"D Del Prete","year":"2016","unstructured":"Del Prete, D., Rice, R. C., Rajadhyaksha, A. M. & D\u2019Adamio, L. Amyloid precursor protein (APP) may act as a substrate and a recognition unit for CRL4CRBN and Stub1 E3 ligases facilitating ubiquitination of proteins involved in presynaptic functions and neurodegeneration. J. Biol. Chem. 291, 17209\u201317227 (2016).","journal-title":"J. Biol. Chem."},{"key":"1426_CR44","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.18632\/oncotarget.27973","volume":"12","author":"A Thakurta","year":"2021","unstructured":"Thakurta, A., Pierceall, W. E., Amatangelo, M. D., Flynt, E. & Agarwal, A. Developing next generation immunomodulatory drugs and their combinations in multiple myeloma. Oncotarget 12, 1555\u20131563 (2021).","journal-title":"Oncotarget"},{"key":"1426_CR45","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1073\/pnas.141230798","volume":"98","author":"KM Sakamoto","year":"2001","unstructured":"Sakamoto, K. M. et al. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl Acad. Sci. USA 98, 8554\u20138559 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1426_CR46","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1126\/science.aab1433","volume":"348","author":"GE Winter","year":"2015","unstructured":"Winter, G. E. et al. Drug development. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348, 1376\u20131381 (2015).","journal-title":"Science"},{"key":"1426_CR47","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","volume":"22","author":"J Lu","year":"2015","unstructured":"Lu, J. et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem. Biol. 22, 755\u2013763 (2015).","journal-title":"Chem. Biol."},{"key":"1426_CR48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","volume":"31","author":"M Pettersson","year":"2019","unstructured":"Pettersson, M. & Crews, C. M. PROteolysis TArgeting Chimeras (PROTACs) \u2014 past, present and future. Drug Discov. Today Technol. 31, 15\u201327 (2019).","journal-title":"Drug Discov. Today Technol."},{"key":"1426_CR49","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1038\/s41591-023-02635-7","volume":"29","author":"L Ackerman","year":"2023","unstructured":"Ackerman, L. et al. IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial. Nat. Med. 29, 3127\u20133136 (2023).","journal-title":"Nat. Med."},{"key":"1426_CR50","unstructured":"Kymera therapeutics announces Sanofi IRAK4 collaboration update. GlobeNewswire https:\/\/www.globenewswire.com\/news-release\/2025\/06\/25\/3104958\/0\/en\/Kymera-Therapeutics-Announces-Sanofi-IRAK4-Collaboration-Update.html (2025)."},{"key":"1426_CR51","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2024-eular.2675","volume":"83","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. POS0057 KPG-818, a novel cereblon modulator in patients with systemic lupus erythematous: results of a randomize, double-blind, placebo-controlled, phase 2a study. Ann. Rheum. Dis. 83, 329\u2013330 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1426_CR52","doi-asserted-by":"publisher","first-page":"103643","DOI":"10.1016\/j.drudis.2023.103643","volume":"28","author":"M Hemkens","year":"2023","unstructured":"Hemkens, M., Stamp, K., Loberg, L. I., Moreau, K. & Hart, T. Industry perspective on the nonclinical safety assessment of heterobifunctional degraders. Drug Discov. Today 28, 103643 (2023).","journal-title":"Drug Discov. Today"},{"key":"1426_CR53","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ceb.2015.10.004","volume":"37","author":"AA Guirguis","year":"2015","unstructured":"Guirguis, A. A. & Ebert, B. L. Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond. Curr. Opin. Cell Biol. 37, 61\u201367 (2015).","journal-title":"Curr. Opin. Cell Biol."},{"key":"1426_CR54","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nature14610","volume":"523","author":"J Kr\u00f6nke","year":"2015","unstructured":"Kr\u00f6nke, J. et al. Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS. Nature 523, 183\u2013188 (2015).","journal-title":"Nature"},{"key":"1426_CR55","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nsmb.2874","volume":"21","author":"PP Chamberlain","year":"2014","unstructured":"Chamberlain, P. P. et al. Structure of the human cereblon\u2013DDB1\u2013lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat. Struct. Mol. Biol. 21, 803\u2013809 (2014).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1426_CR56","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41594-020-0405-9","volume":"27","author":"ME Matyskiela","year":"2020","unstructured":"Matyskiela, M. E. et al. Crystal structure of the SALL4\u2013pomalidomide\u2013cereblon\u2013DDB1 complex. Nat. Struct. Mol. Biol. 27, 319\u2013322 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1426_CR57","doi-asserted-by":"publisher","DOI":"10.1126\/science.aat0572","volume":"362","author":"QL Sievers","year":"2018","unstructured":"Sievers, Q. L. et al. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science 362, eaat0572 (2018).","journal-title":"Science"},{"key":"1426_CR58","doi-asserted-by":"publisher","first-page":"6160","DOI":"10.1021\/acs.jcim.2c01033","volume":"62","author":"L Wang","year":"2022","unstructured":"Wang, L., Li, F.-L., Ma, X.-Y., Cang, Y. & Bai, F. PPI-miner: a structure and sequence motif co-driven protein\u2013protein interaction mining and modeling computational method. J. Chem. Inf. Model. 62, 6160\u20136171 (2022).","journal-title":"J. Chem. Inf. Model."},{"key":"1426_CR59","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1146\/annurev-pharmtox-022123-104147","volume":"64","author":"V Oleinikovas","year":"2024","unstructured":"Oleinikovas, V., Gainza, P., Ryckmans, T., Fasching, B. & Thom\u00e4, N. H. From thalidomide to rational molecular glue design for targeted protein degradation. Annu. Rev. Pharmacol. Toxicol. 64, 291\u2013312 (2024).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"1426_CR60","doi-asserted-by":"publisher","DOI":"10.1126\/science.adt6736","volume":"389","author":"G Petzold","year":"2025","unstructured":"Petzold, G. et al. Mining the CRBN target space redefines rules for molecular glue\u2013induced neosubstrate recognition. Science 389, eadt6736 (2025).","journal-title":"Science"},{"key":"1426_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62099-w","volume":"16","author":"K Baek","year":"2025","unstructured":"Baek, K. et al. Unveiling the hidden interactome of CRBN molecular glues. Nat. Commun. 16, 6831 (2025).","journal-title":"Nat. Commun."},{"key":"1426_CR62","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nature18611","volume":"535","author":"ME Matyskiela","year":"2016","unstructured":"Matyskiela, M. E. et al. A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase. Nature 535, 252\u2013257 (2016).","journal-title":"Nature"},{"key":"1426_CR63","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1182\/blood.2020008676","volume":"137","author":"C Surka","year":"2021","unstructured":"Surka, C. et al. CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells. Blood 137, 661\u2013677 (2021).","journal-title":"Blood"},{"key":"1426_CR64","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1158\/1538-7445.AM2024-3294","volume":"84","author":"R Tiedt","year":"2024","unstructured":"Tiedt, R. et al. Abstract 3294: The GSPT1 molecular glue degrader MRT-2359 is active against prostate cancer. Cancer Res. 84, 3294 (2024).","journal-title":"Cancer Res."},{"key":"1426_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62829-0","volume":"16","author":"M Steger","year":"2025","unstructured":"Steger, M. et al. Unbiased mapping of cereblon neosubstrate landscape by high-throughput proteomics. Nat. Commun. 16, 7773 (2025).","journal-title":"Nat. Commun."},{"key":"1426_CR66","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.chembiol.2018.11.006","volume":"26","author":"M Brand","year":"2019","unstructured":"Brand, M. et al. Homolog-selective degradation as a strategy to probe the function of CDK6 in AML. Cell Chem. Biol. 26, 300\u2013306.e9 (2019).","journal-title":"Cell Chem. Biol."},{"key":"1426_CR67","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1182\/blood.2020006846","volume":"138","author":"Y Chang","year":"2021","unstructured":"Chang, Y. et al. Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia. Blood 138, 2313\u20132326 (2021).","journal-title":"Blood"},{"key":"1426_CR68","doi-asserted-by":"publisher","first-page":"7042","DOI":"10.1021\/acs.jmedchem.9b00516","volume":"62","author":"H Wu","year":"2019","unstructured":"Wu, H. et al. Development of multifunctional histone deacetylase 6 degraders with potent antimyeloma activity. J. Med. Chem. 62, 7042\u20137057 (2019).","journal-title":"J. Med. Chem."},{"key":"1426_CR69","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","volume":"25","author":"GM Burslem","year":"2018","unstructured":"Burslem, G. M. et al. The advantages of targeted protein degradation over inhibition: an RTK case study. Cell Chem. Biol. 25, 67\u201377.e3 (2018).","journal-title":"Cell Chem. Biol."},{"key":"1426_CR70","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1021\/acsmedchemlett.1c00368","volume":"12","author":"A Bricelj","year":"2021","unstructured":"Bricelj, A. et al. Influence of linker attachment points on the stability and neosubstrate degradation of cereblon ligands. ACS Med. Chem. Lett. 12, 1733\u20131738 (2021).","journal-title":"ACS Med. Chem. Lett."},{"key":"1426_CR71","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1021\/acsmedchemlett.1c00650","volume":"13","author":"LJ Alcock","year":"2022","unstructured":"Alcock, L. J. et al. Development of potent and selective Janus kinase 2\/3 directing PG\u2013PROTACs. ACS Med. Chem. Lett. 13, 475\u2013482 (2022).","journal-title":"ACS Med. Chem. Lett."},{"key":"1426_CR72","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/0041-008X(65)90095-5","volume":"7","author":"ID Fratta","year":"1965","unstructured":"Fratta, I. D., Sigg, E. B. & Maiorana, K. Teratogenic effects of thalidomide in rabbits, rats, hamsters, and mice. Toxicol. Appl. Pharmacol. 7, 268\u2013286 (1965).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"1426_CR73","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/bdrc.21096","volume":"105","author":"N Vargesson","year":"2015","unstructured":"Vargesson, N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res. C Embryo Today 105, 140\u2013156 (2015).","journal-title":"Birth Defects Res. C Embryo Today"},{"key":"1426_CR74","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1182\/blood-2012-02-412783","volume":"120","author":"M Chesi","year":"2012","unstructured":"Chesi, M. et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 120, 376\u2013385 (2012).","journal-title":"Blood"},{"key":"1426_CR75","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1182\/blood-2018-05-852798","volume":"132","author":"EC Fink","year":"2018","unstructured":"Fink, E. C. et al. Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice. Blood 132, 1535\u20131544 (2018).","journal-title":"Blood"},{"key":"1426_CR76","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1182\/blood.2019003749","volume":"135","author":"T Tochigi","year":"2020","unstructured":"Tochigi, T. et al. Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug-induced thrombocytopenia. Blood 135, 2146\u20132158 (2020).","journal-title":"Blood"},{"key":"1426_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18488-4","volume":"11","author":"H Furihata","year":"2020","unstructured":"Furihata, H. et al. Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide. Nat. Commun. 11, 4578 (2020).","journal-title":"Nat. Commun."},{"key":"1426_CR78","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0140-6736(62)92665-X","volume":"279","author":"W Lenz","year":"1962","unstructured":"Lenz, W., Pfeiffer, R. A., Kosenow, W. & Hayman, D. J. Thalidomide and congenital abnormalities. Lancet 279, 45\u201346 (1962).","journal-title":"Lancet"},{"key":"1426_CR79","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/S0140-6736(61)90927-8","volume":"278","author":"WG McBride","year":"1961","unstructured":"McBride, W. G. Thalidomide and congenital abnormalities. Lancet 278, 1358 (1961).","journal-title":"Lancet"},{"key":"1426_CR80","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/tera.1420380303","volume":"38","author":"W Lenz","year":"1988","unstructured":"Lenz, W. A short history of thalidomide embryopathy. Teratology 38, 203\u2013215 (1988).","journal-title":"Teratology"},{"key":"1426_CR81","doi-asserted-by":"publisher","first-page":"12703","DOI":"10.1073\/pnas.1307684110","volume":"110","author":"C Mahony","year":"2013","unstructured":"Mahony, C. et al. Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro. Proc. Natl Acad. Sci. USA 110, 12703\u201312708 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1426_CR82","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3390\/ph16030368","volume":"16","author":"W Dong","year":"2023","unstructured":"Dong, W. et al. Augmentation of pectoral fin teratogenicity by thalidomide in human cytochrome P450 3A-expressing zebrafish. Pharmaceuticals 16, 368 (2023).","journal-title":"Pharmaceuticals"},{"key":"1426_CR83","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.reprotox.2022.10.005","volume":"114","author":"JY Hui","year":"2022","unstructured":"Hui, J. Y., Fuchs, A. & Kumar, G. Embryo-fetal exposure and developmental outcome of lenalidomide following oral administration to pregnant cynomolgus monkeys. Reprod. Toxicol. 114, 57\u201365 (2022).","journal-title":"Reprod. Toxicol."},{"key":"1426_CR84","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/bdrb.20115","volume":"80","author":"MS Christian","year":"2007","unstructured":"Christian, M. S. et al. Evaluation of the developmental toxicity of lenalidomide in rabbits. Birth Defects Res. B Dev. Reprod. Toxicol. 80, 188\u2013207 (2007).","journal-title":"Birth Defects Res. B Dev. Reprod. Toxicol."},{"key":"1426_CR85","unstructured":"Revlimid\u00ae pharmacology\/toxicology review and evaluation. FDA https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2005\/021880s000_Revlimid_PharmR.pdf (2005)."},{"key":"1426_CR86","unstructured":"Pomalyst (pomalidomide) pharmacology review(s). FDA https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204026Orig1s000PharmR.pdf (2012)."},{"key":"1426_CR87","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020105375","volume":"40","author":"S Yamanaka","year":"2021","unstructured":"Yamanaka, S. et al. Thalidomide and its metabolite 5-hydroxythalidomide induce teratogenicity via the cereblon neosubstrate PLZF. EMBO J. 40, e105375 (2021).","journal-title":"EMBO J."},{"key":"1426_CR88","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1177\/2472555220984372","volume":"26","author":"AL Chernobrovkin","year":"2021","unstructured":"Chernobrovkin, A. L. et al. A tale of two tails: efficient profiling of protein degraders by specific functional and target engagement readouts. SLAS Discov. 26, 534\u2013546 (2021).","journal-title":"SLAS Discov."},{"key":"1426_CR89","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/humu.20215","volume":"26","author":"J Kohlhase","year":"2005","unstructured":"Kohlhase, J. et al. SALL4 mutations in Okihiro syndrome (Duane-radial ray syndrome), acro-renal-ocular syndrome, and related disorders. Hum. Mutat. 26, 176\u2013183 (2005).","journal-title":"Hum. Mutat."},{"key":"1426_CR90","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/bdra.20050","volume":"70","author":"J Kohlhase","year":"2004","unstructured":"Kohlhase, J. & Holmes, L. B. Mutations in SALL4 in malformed father and daughter postulated previously due to reflect mutagenesis by thalidomide. Birth Defects Res. A Clin. Mol. Teratol. 70, 550\u2013551 (2004).","journal-title":"Birth Defects Res. A Clin. Mol. Teratol."},{"key":"1426_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2024.100797","volume":"23","author":"JD Federspiel","year":"2024","unstructured":"Federspiel, J. D. et al. Differential analysis of cereblon neosubstrates in rabbit embryos using targeted proteomics. Mol. Cell. Proteom. 23, 100797 (2024).","journal-title":"Mol. Cell. Proteom."},{"key":"1426_CR92","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/s42003-021-02801-y","volume":"4","author":"N Shimizu","year":"2021","unstructured":"Shimizu, N. et al. PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates. Commun. Biol. 4, 1277 (2021).","journal-title":"Commun. Biol."},{"key":"1426_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40385-9","volume":"14","author":"S Yamanaka","year":"2023","unstructured":"Yamanaka, S. et al. Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation. Nat. Commun. 14, 4683 (2023).","journal-title":"Nat. Commun."},{"key":"1426_CR94","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/76014","volume":"25","author":"M Barna","year":"2000","unstructured":"Barna, M., Hawe, N., Niswander, L. & Pandolfi, P. P. Plzf regulates limb and axial skeletal patterning. Nat. Genet. 25, 166\u2013172 (2000).","journal-title":"Nat. Genet."},{"key":"1426_CR95","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1136\/jmg.2008.059451","volume":"45","author":"S Fischer","year":"2008","unstructured":"Fischer, S. et al. Biallelic loss of function of the promyelocytic leukaemia zinc finger (PLZF) gene causes severe skeletal defects and genital hypoplasia. J. Med. Genet. 45, 731\u2013737 (2008).","journal-title":"J. Med. Genet."},{"key":"1426_CR96","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1038\/s41589-019-0366-7","volume":"15","author":"T Asatsuma-Okumura","year":"2019","unstructured":"Asatsuma-Okumura, T. et al. p63 is a cereblon substrate involved in thalidomide teratogenicity. Nat. Chem. Biol. 15, 1077\u20131084 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"1426_CR97","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0092-8674(00)81646-3","volume":"99","author":"J Celli","year":"1999","unstructured":"Celli, J. et al. Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell 99, 143\u2013153 (1999).","journal-title":"Cell"},{"key":"1426_CR98","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/19531","volume":"398","author":"AA Mills","year":"1999","unstructured":"Mills, A. A. et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398, 708\u2013713 (1999).","journal-title":"Nature"},{"key":"1426_CR99","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1093\/hmg\/ddu096","volume":"23","author":"M Restelli","year":"2014","unstructured":"Restelli, M. et al. DLX5, FGF8 and the Pin1 isomerase control \u0394Np63\u03b1 protein stability during limb development: a regulatory loop at the basis of the SHFM and EEC congenital malformations. Hum. Mol. Genet. 23, 3830\u20133842 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"1426_CR100","doi-asserted-by":"publisher","first-page":"7300","DOI":"10.1073\/pnas.1214498110","volume":"110","author":"A Terrinoni","year":"2013","unstructured":"Terrinoni, A. et al. Role of p63 and the Notch pathway in cochlea development and sensorineural deafness. Proc. Natl Acad. Sci. USA 110, 7300\u20137305 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1426_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01641-3","volume":"7","author":"A Khalil","year":"2017","unstructured":"Khalil, A. et al. A HAND to TBX5 explains the link between thalidomide and cardiac diseases. Sci. Rep. 7, 1416 (2017).","journal-title":"Sci. Rep."},{"key":"1426_CR102","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1242\/dev.00473","volume":"130","author":"C Rallis","year":"2003","unstructured":"Rallis, C. et al. Tbx5 is required for forelimb bud formation and continued outgrowth. Development 130, 2741\u20132751 (2003).","journal-title":"Development"},{"key":"1426_CR103","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1242\/dev.129.19.4635","volume":"129","author":"DM Garrity","year":"2002","unstructured":"Garrity, D. M., Childs, S. & Fishman, M. C. The heartstrings mutation in zebrafish causes heart\/fin Tbx5 deficiency syndrome. Development 129, 4635\u20134645 (2002).","journal-title":"Development"},{"key":"1426_CR104","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006540","volume":"96","author":"X Peng","year":"2017","unstructured":"Peng, X. et al. Thalidomide results in diminished ovarian reserve in reproductive age female IBD patients. Medicine 96, e6540 (2017).","journal-title":"Medicine"},{"key":"1426_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15398","volume":"8","author":"J An","year":"2017","unstructured":"An, J. et al. pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase. Nat. Commun. 8, 15398 (2017).","journal-title":"Nat. Commun."},{"key":"1426_CR106","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1297484","volume":"14","author":"L Qi","year":"2023","unstructured":"Qi, L. et al. Immune and oxidative stress disorder in ovulation-dysfunction women revealed by single-cell transcriptome. Front. Immunol. 14, 1297484 (2023).","journal-title":"Front. Immunol."},{"key":"1426_CR107","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1074\/jbc.M116.767061","volume":"292","author":"K Xu","year":"2017","unstructured":"Xu, K. et al. Maternal Sall4 is indispensable for epigenetic maturation of mouse oocytes. J. Biol. Chem. 292, 1798\u20131807 (2017).","journal-title":"J. Biol. Chem."},{"key":"1426_CR108","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.semcdb.2016.03.002","volume":"59","author":"C Boitani","year":"2016","unstructured":"Boitani, C., Di Persio, S., Esposito, V. & Vicini, E. Spermatogonial cells: mouse, monkey and man comparison. Semin. Cell Dev. Biol. 59, 79\u201388 (2016).","journal-title":"Semin. Cell Dev. Biol."},{"key":"1426_CR109","doi-asserted-by":"publisher","first-page":"173","DOI":"10.5194\/pb-4-173-2017","volume":"4","author":"S Sharma","year":"2017","unstructured":"Sharma, S. et al. Male germline stem cells in non-human primates. Primate Biol. 4, 173\u2013184 (2017).","journal-title":"Primate Biol."},{"key":"1426_CR110","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1071\/RD18252","volume":"31","author":"DZJ Clotaire","year":"2019","unstructured":"Clotaire, D. Z. J., Wei, Y., Yu, X., Ousman, T. & Hua, J. Functions of promyelocytic leukaemia zinc finger (Plzf) in male germline stem cell development and differentiation. Reprod. Fertil. Dev. 31, 1315\u20131320 (2019).","journal-title":"Reprod. Fertil. Dev."},{"key":"1426_CR111","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/ng1366","volume":"36","author":"FW Buaas","year":"2004","unstructured":"Buaas, F. W. et al. Plzf is required in adult male germ cells for stem cell self-renewal. Nat. Genet. 36, 647\u2013652 (2004).","journal-title":"Nat. Genet."},{"key":"1426_CR112","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/ng1367","volume":"36","author":"JA Costoya","year":"2004","unstructured":"Costoya, J. A. et al. Essential role of Plzf in maintenance of spermatogonial stem cells. Nat. Genet. 36, 653\u2013659 (2004).","journal-title":"Nat. Genet."},{"key":"1426_CR113","unstructured":"THALOMID (thalidomide) US Label. FDA https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/020785s071lbl.pdf (2023)."},{"key":"1426_CR114","unstructured":"REVLIMID (lenalidomide) US Label. FDA https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/021880s067lbl.pdf (2023)."},{"key":"1426_CR115","unstructured":"POMALYST\u00ae (pomalidomide) US Label. FDA https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/204026s031lbl.pdf (2023)."},{"key":"1426_CR116","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3109\/10428194.2012.728597","volume":"54","author":"YX Zhu","year":"2013","unstructured":"Zhu, Y. X., Kortuem, K. M. & Stewart, A. K. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk. Lymphoma 54, 683\u2013687 (2013).","journal-title":"Leuk. Lymphoma"},{"key":"1426_CR117","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard, F. et al. Multiple myeloma. Nat. Rev. Dis. Primers 10, 45 (2024).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1426_CR118","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00277-018-3284-y","volume":"97","author":"M Chen","year":"2018","unstructured":"Chen, M. et al. Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies. Ann. Hematol. 97, 925\u2013944 (2018).","journal-title":"Ann. Hematol."},{"key":"1426_CR119","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.apsb.2016.06.002","volume":"6","author":"Y Fan","year":"2016","unstructured":"Fan, Y. & Lu, D. The Ikaros family of zinc-finger proteins. Acta Pharm. Sin. B 6, 513\u2013521 (2016).","journal-title":"Acta Pharm. Sin. B"},{"key":"1426_CR120","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/bloodadvances.2017010348","volume":"2","author":"S Li","year":"2018","unstructured":"Li, S. et al. IMiD compounds affect CD34+ cell fate and maturation via CRBN-induced IKZF1 degradation. Blood Adv. 2, 492\u2013504 (2018).","journal-title":"Blood Adv."},{"key":"1426_CR121","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1084\/jem.190.9.1201","volume":"190","author":"A Nichogiannopoulou","year":"1999","unstructured":"Nichogiannopoulou, A., Trevisan, M., Neben, S., Friedrich, C. & Georgopoulos, K. Defects in hemopoietic stem cell activity in Ikaros mutant mice. J. Exp. Med. 190, 1201\u20131214 (1999).","journal-title":"J. Exp. Med."},{"key":"1426_CR122","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1073\/pnas.022412699","volume":"99","author":"RA Lopez","year":"2002","unstructured":"Lopez, R. A., Schoetz, S., DeAngelis, K., O\u2019Neill, D. & Bank, A. Multiple hematopoietic defects and delayed globin switching in Ikaros null mice. Proc. Natl Acad. Sci. USA 99, 602\u2013607 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1426_CR123","doi-asserted-by":"publisher","first-page":"866582","DOI":"10.3389\/fimmu.2022.866582","volume":"13","author":"M Yamashita","year":"2022","unstructured":"Yamashita, M. & Morio, T. AIOLOS variants causing immunodeficiency in human and mice. Front. Immunol. 13, 866582 (2022).","journal-title":"Front. Immunol."},{"key":"1426_CR124","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/s41590-021-00951-z","volume":"22","author":"M Yamashita","year":"2021","unstructured":"Yamashita, M. et al. A variant in human AIOLOS impairs adaptive immunity by interfering with IKAROS. Nat. Immunol. 22, 893\u2013903 (2021).","journal-title":"Nat. Immunol."},{"key":"1426_CR125","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20211118","volume":"218","author":"HS Kuehn","year":"2021","unstructured":"Kuehn, H. S. et al. T and B cell abnormalities, pneumocystis pneumonia, and chronic lymphocytic leukemia associated with an AIOLOS defect in patients. J. Exp. Med. 218, e20211118 (2021).","journal-title":"J. Exp. Med."},{"key":"1426_CR126","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S1074-7613(00)80637-8","volume":"9","author":"JH Wang","year":"1998","unstructured":"Wang, J. H. et al. Aiolos regulates B cell activation and maturation to effector state. Immunity 9, 543\u2013553 (1998).","journal-title":"Immunity"},{"key":"1426_CR127","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abe3454","volume":"6","author":"I Hetem\u00e4ki","year":"2021","unstructured":"Hetem\u00e4ki, I. et al. Loss-of-function mutation in IKZF2 leads to immunodeficiency with dysregulated germinal center reactions and reduction of MAIT cells. Sci. Immunol. 6, eabe3454 (2021).","journal-title":"Sci. Immunol."},{"key":"1426_CR128","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abe3981","volume":"6","author":"T Shahin","year":"2021","unstructured":"Shahin, T. et al. Germline biallelic mutation affecting the transcription factor Helios causes pleiotropic defects of immunity. Sci. Immunol. 6, eabe3981 (2021).","journal-title":"Sci. Immunol."},{"key":"1426_CR129","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20202317","volume":"218","author":"G Cova","year":"2021","unstructured":"Cova, G. et al. Helios represses megakaryocyte priming in hematopoietic stem and progenitor cells. J. Exp. Med. 218, e20202317 (2021).","journal-title":"J. Exp. Med."},{"key":"1426_CR130","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1126\/science.aad0616","volume":"350","author":"H-J Kim","year":"2015","unstructured":"Kim, H.-J. et al. Stable inhibitory activity of regulatory T cells requires the transcription factor Helios. Science 350, 334\u2013339 (2015).","journal-title":"Science"},{"key":"1426_CR131","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4049\/jimmunol.1501704","volume":"196","author":"M Sebastian","year":"2016","unstructured":"Sebastian, M. et al. Helios controls a limited subset of regulatory T cell functions. J. Immunol. 196, 144\u2013155 (2016).","journal-title":"J. Immunol."},{"key":"1426_CR132","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1136\/annrheumdis-2022-222212","volume":"81","author":"PE Lipsky","year":"2022","unstructured":"Lipsky, P. E. et al. Biological impact of iberdomide in patients with active systemic lupus erythematosus. Ann. Rheum. Dis. 81, 1136\u20131142 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1426_CR133","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ccr.2014.08.001","volume":"26","author":"RK Schneider","year":"2014","unstructured":"Schneider, R. K. et al. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell 26, 509\u2013520 (2014).","journal-title":"Cancer Cell"},{"key":"1426_CR134","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s11060-014-1632-x","volume":"121","author":"JLM Jongen","year":"2015","unstructured":"Jongen, J. L. M., Broijl, A. & Sonneveld, P. Chemotherapy-induced peripheral neuropathies in hematological malignancies. J. Neuro-Oncol. 121, 229\u2013237 (2015).","journal-title":"J. Neuro-Oncol."},{"key":"1426_CR135","first-page":"37","volume":"6","author":"S Grammatico","year":"2016","unstructured":"Grammatico, S., Cesini, L. & Petrucci, M. T. Managing treatment-related peripheral neuropathy in patients with multiple myeloma. Blood Lymphat. Cancer 6, 37\u201347 (2016).","journal-title":"Blood Lymphat. Cancer"},{"key":"1426_CR136","first-page":"194","volume":"1","author":"IM Ghobrial","year":"2003","unstructured":"Ghobrial, I. M. & Rajkumar, S. V. Management of thalidomide toxicity. J. Support. Oncol. 1, 194\u2013205 (2003).","journal-title":"J. Support. Oncol."},{"key":"1426_CR137","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1212\/01.WNL.0000037480.59194.85","volume":"59","author":"V Chaudhry","year":"2002","unstructured":"Chaudhry, V. et al. Thalidomide-induced neuropathy. Neurology 59, 1872\u20131875 (2002).","journal-title":"Neurology"},{"key":"1426_CR138","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3390\/ijms20061451","volume":"20","author":"R Zaj\u0105czkowska","year":"2019","unstructured":"Zaj\u0105czkowska, R. et al. Mechanisms of chemotherapy-induced peripheral neuropathy. Int. J. Mol. Sci. 20, 1451 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"1426_CR139","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1177\/01926233241300452","volume":"52","author":"K Palyada","year":"2024","unstructured":"Palyada, K. et al. Session 5: protein degraders. Toxicol. Pathol. 52, 553\u2013565 (2024).","journal-title":"Toxicol. Pathol."},{"key":"1426_CR140","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.15082","volume":"5","author":"L Isbel","year":"2016","unstructured":"Isbel, L. et al. Wiz binds active promoters and CTCF-binding sites and is required for normal behaviour in the mouse. eLife 5, e15082 (2016).","journal-title":"eLife"},{"key":"1426_CR141","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1093\/nar\/gkac042","volume":"50","author":"T Aberle","year":"2022","unstructured":"Aberle, T. et al. Transcription factor Zfp276 drives oligodendroglial differentiation and myelination by switching off the progenitor cell program. Nucleic Acids Res. 50, 1951\u20131968 (2022).","journal-title":"Nucleic Acids Res."},{"key":"1426_CR142","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1523\/JNEUROSCI.2081-17.2018","volume":"38","author":"T-Y Choi","year":"2018","unstructured":"Choi, T.-Y. et al. Cereblon maintains synaptic and cognitive function by regulating BK channel. J. Neurosci. 38, 3571\u20133583 (2018).","journal-title":"J. Neurosci."},{"key":"1426_CR143","doi-asserted-by":"publisher","first-page":"29573","DOI":"10.1074\/jbc.M113.472092","volume":"288","author":"G Xu","year":"2013","unstructured":"Xu, G., Jiang, X. & Jaffrey, S. R. A mental retardation-linked nonsense mutation in cereblon is rescued by proteasome inhibition. J. Biol. Chem. 288, 29573\u201329585 (2013).","journal-title":"J. Biol. Chem."},{"key":"1426_CR144","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10048-008-0128-2","volume":"9","author":"JJ Higgins","year":"2008","unstructured":"Higgins, J. J., Hao, J., Kosofsky, B. E. & Rajadhyaksha, A. M. Dysregulation of large-conductance Ca2+-activated K+ channel expression in nonsyndromal mental retardation due to a cereblon p.R419X mutation. Neurogenetics 9, 219\u2013223 (2008).","journal-title":"Neurogenetics"},{"key":"1426_CR145","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1111\/bph.15014","volume":"177","author":"K Moreau","year":"2020","unstructured":"Moreau, K. et al. Proteolysis-targeting chimeras in drug development: a safety perspective. Br. J. Pharmacol. 177, 1709\u20131718 (2020).","journal-title":"Br. J. Pharmacol."},{"key":"1426_CR146","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/j.1365-2141.2005.05914.x","volume":"132","author":"A Glasmacher","year":"2006","unstructured":"Glasmacher, A. et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br. J. Haematol. 132, 584\u2013593 (2006).","journal-title":"Br. J. Haematol."},{"key":"1426_CR147","unstructured":"Thalidomide pharmacology review(s). FDA https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/98\/020785s000_Thalidomide_PharmR.pdf (1998)."},{"key":"1426_CR148","unstructured":"IKZF3 protein expression summary. The Human Protein Atlas https:\/\/www.proteinatlas.org\/ENSG00000161405-IKZF3 (2024)."},{"key":"1426_CR149","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41385-021-00416-4","volume":"14","author":"JM Felton","year":"2021","unstructured":"Felton, J. M. et al. Aiolos regulates eosinophil migration into tissues. Mucosal Immunol. 14, 1271\u20131281 (2021).","journal-title":"Mucosal Immunol."},{"key":"1426_CR150","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1038\/s41385-021-00431-5","volume":"14","author":"J Qiu","year":"2021","unstructured":"Qiu, J. et al. Tissue signals imprint Aiolos expression in ILC2s to modulate type 2 immunity. Mucosal Immunol. 14, 1306\u20131322 (2021).","journal-title":"Mucosal Immunol."},{"key":"1426_CR151","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1128\/MCB.00988-15","volume":"36","author":"YV Katlinskaya","year":"2016","unstructured":"Katlinskaya, Y. V. et al. Type I interferons control proliferation and function of the intestinal epithelium. Mol. Cell. Biol. 36, 1124\u20131135 (2016).","journal-title":"Mol. Cell. Biol."},{"key":"1426_CR152","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/bjh.15972","volume":"186","author":"R Mlak","year":"2019","unstructured":"Mlak, R. et al. Polymorphisms in the promotor region of the CRBN gene as a predictive factor for peripheral neuropathy in the course of thalidomide-based chemotherapy in multiple myeloma patients. Br. J. Haematol. 186, 695\u2013705 (2019).","journal-title":"Br. J. Haematol."},{"key":"1426_CR153","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.reprotox.2016.10.003","volume":"66","author":"FSL Vianna","year":"2016","unstructured":"Vianna, F. S. L. et al. Genomic and in silico analyses of CRBN gene and thalidomide embryopathy in humans. Reprod. Toxicol. 66, 99\u2013106 (2016).","journal-title":"Reprod. Toxicol."},{"key":"1426_CR154","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.3390\/jcm13061574","volume":"13","author":"S Barachini","year":"2024","unstructured":"Barachini, S., Buda, G. & Petrini, I. Cardiovascular toxicity of antineoplastic treatments in hematological diseases: focus on molecular mechanisms to improve therapeutic management. J. Clin. Med. 13, 1574 (2024).","journal-title":"J. Clin. Med."},{"key":"1426_CR155","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1160\/TH06-09-0494","volume":"97","author":"RN El Accaoui","year":"2007","unstructured":"El Accaoui, R. N., Shamseddeen, W. A. & Taher, A. T. Thalidomide and thrombosis. A meta-analysis. Thromb. Haemost. 97, 1031\u20131036 (2007).","journal-title":"Thromb. Haemost."},{"key":"1426_CR156","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","volume":"11","author":"SV Rajkumar","year":"2010","unstructured":"Rajkumar, S. V. et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 11, 29\u201337 (2010).","journal-title":"Lancet Oncol."},{"key":"1426_CR157","unstructured":"Lenalidomide: risk of thrombosis and thromboembolism. Medicines and Healthcare products Regulatory Agency https:\/\/www.gov.uk\/drug-safety-update\/lenalidomide-risk-of-thrombosis-and-thromboembolism (2014)."},{"key":"1426_CR158","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.4065\/80.12.1568","volume":"80","author":"R Baz","year":"2005","unstructured":"Baz, R. et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin. Proc. 80, 1568\u20131574 (2005).","journal-title":"Mayo Clin. Proc."},{"key":"1426_CR159","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/ajh.23504","volume":"88","author":"T Bagratuni","year":"2013","unstructured":"Bagratuni, T. et al. Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. Am. J. Hematol. 88, 765\u2013770 (2013).","journal-title":"Am. J. Hematol."},{"key":"1426_CR160","doi-asserted-by":"publisher","first-page":"4924","DOI":"10.1182\/blood-2008-02-140434","volume":"112","author":"DC Johnson","year":"2008","unstructured":"Johnson, D. C. et al. Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood 112, 4924\u20134934 (2008).","journal-title":"Blood"},{"key":"1426_CR161","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1001\/jamaoncol.2016.3350","volume":"3","author":"W Li","year":"2017","unstructured":"Li, W. et al. Cardiovascular and thrombotic complications of novel multiple myeloma therapies: a review. JAMA Oncol. 3, 980\u2013988 (2017).","journal-title":"JAMA Oncol."},{"key":"1426_CR162","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/hon.2959","volume":"40","author":"A Das","year":"2022","unstructured":"Das, A. et al. Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: a network meta-analysis of randomized clinical trials. Hematol. Oncol. 40, 233\u2013242 (2022).","journal-title":"Hematol. Oncol."},{"key":"1426_CR163","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1093\/eurheartj\/ehac072","volume":"43","author":"N Park","year":"2022","unstructured":"Park, N. et al. Cereblon contributes to cardiac dysfunction by degrading Cav1.2\u03b1. Eur. Heart J. 43, 1973\u20131989 (2022).","journal-title":"Eur. Heart J."},{"key":"1426_CR164","unstructured":"Gollob, J. Phase 1 single and multiple ascending dose trial of KT 474 in healthy volunteers. Kymera Therapeutics https:\/\/www.kymeratx.com\/wp-content\/uploads\/2022\/10\/Kymera-TPD-Plenary_Jared_Gollob_-20221026_.pdf (2022)."},{"key":"1426_CR165","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1158\/1078-0432.CCR-24-2583","volume":"31","author":"JA Livingston","year":"2025","unstructured":"Livingston, J. A. et al. A phase I study of FHD-609, a heterobifunctional degrader of bromodomain-containing protein 9, in patients with advanced synovial sarcoma or SMARCB1-deficient tumors. Clin. Cancer Res. 31, 628\u2013638 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1426_CR166","unstructured":"LeCureux, L. et al. Evidence of off-target hERG degradation with a cereblon modulator. The Toxicologist, Supplement to Toxicol. Sci., Abstract 4666 (2024)."},{"key":"1426_CR167","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.exphem.2014.03.005","volume":"42","author":"A Bolomsky","year":"2014","unstructured":"Bolomsky, A. et al. Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro. Exp. Hematol. 42, 516\u2013525 (2014).","journal-title":"Exp. Hematol."},{"key":"1426_CR168","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-59542-x","volume":"10","author":"DG Belair","year":"2020","unstructured":"Belair, D. G. et al. Thalidomide inhibits human iPSC mesendoderm differentiation by modulating CRBN-dependent degradation of SALL4. Sci. Rep. 10, 2864 (2020).","journal-title":"Sci. Rep."},{"key":"1426_CR169","doi-asserted-by":"publisher","first-page":"55405","DOI":"10.18632\/oncotarget.19265","volume":"8","author":"J Guo","year":"2017","unstructured":"Guo, J. et al. Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway. Oncotarget 8, 55405\u201355421 (2017).","journal-title":"Oncotarget"},{"key":"1426_CR170","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1007\/s00198-023-06852-1","volume":"34","author":"D He","year":"2023","unstructured":"He, D. et al. A longitudinal genome-wide association study of bone mineral density mean and variability in the UK Biobank. Osteoporos. Int. 34, 1907\u20131916 (2023).","journal-title":"Osteoporos. Int."},{"key":"1426_CR171","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1136\/annrheumdis-2012-201551","volume":"72","author":"FMK Williams","year":"2013","unstructured":"Williams, F. M. K. et al. Novel genetic variants associated with lumbar disc degeneration in northern Europeans: a meta-analysis of 4600 subjects. Ann. Rheum. Dis. 72, 1141\u20131148 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"1426_CR172","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1365-2133.2005.06747.x","volume":"153","author":"JJ Wu","year":"2005","unstructured":"Wu, J. J., Huang, D. B., Pang, K. R., Hsu, S. & Tyring, S. K. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br. J. Dermatol. 153, 254\u2013273 (2005).","journal-title":"Br. J. Dermatol."},{"key":"1426_CR173","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/01.ico.0000133998.45262.ca","volume":"24","author":"S Srinivasan","year":"2005","unstructured":"Srinivasan, S., Perez-Gomez, I., O\u2019Donnell, C. & Batterbury, M. Corneal endothelial abnormalities associated with thalidomide toxicity. Cornea 24, 103\u2013105 (2005).","journal-title":"Cornea"},{"key":"1426_CR174","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1592\/phco.26.7.1018","volume":"26","author":"AJ Hanje","year":"2006","unstructured":"Hanje, A. J., Shamp, J. L., Thomas, F. B. & Meis, G. M. Thalidomide-induced severe hepatotoxicity. Pharmacotherapy 26, 1018\u20131022 (2006).","journal-title":"Pharmacotherapy"},{"key":"1426_CR175","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1182\/blood-2007-06-097758","volume":"110","author":"S Hussain","year":"2007","unstructured":"Hussain, S., Browne, R., Chen, J. & Parekh, S. Lenalidomide-induced severe hepatotoxicity. Blood 110, 3814 (2007).","journal-title":"Blood"},{"key":"1426_CR176","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/S0140-6736(14)61030-8","volume":"383","author":"RR Veluswamy","year":"2014","unstructured":"Veluswamy, R. R. et al. Adverse drug reaction: pomalidomide-induced liver injury. Lancet 383, 2125\u20132126 (2014).","journal-title":"Lancet"},{"key":"1426_CR177","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2484\/rcr.v2i2.71","volume":"2","author":"SK Khalsa","year":"2007","unstructured":"Khalsa, S. K., Roberts, C. C. & Underhill, M. S. Acute pulmonary toxicity from thalidomide in a patient with multiple myeloma. Radiol. Case Rep. 2, 41\u201343 (2007).","journal-title":"Radiol. Case Rep."},{"key":"1426_CR178","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1378\/chest.10-2082","volume":"140","author":"HL Geyer","year":"2011","unstructured":"Geyer, H. L. et al. Acute lung toxicity related to pomalidomide. Chest 140, 529\u2013533 (2011).","journal-title":"Chest"},{"key":"1426_CR179","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.hrtlng.2013.11.007","volume":"43","author":"J Mankikian","year":"2014","unstructured":"Mankikian, J. et al. Pulmonary toxicity associated with the use of lenalidomide: case report of late-onset acute respiratory distress syndrome and literature review. Heart Lung 43, 120\u2013123 (2014).","journal-title":"Heart Lung"},{"key":"1426_CR180","unstructured":"ICH harmonised tripartite guideline: guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3(R2). ICH Expert Working Group https:\/\/database.ich.org\/sites\/default\/files\/M3_R2__Guideline.pdf (2009)."},{"key":"1426_CR181","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09994-w","author":"VN Dippon","year":"2026","unstructured":"Dippon, V. N. et al. Identification of an allosteric site on the E3 ligase adapter cereblon. Nature https:\/\/doi.org\/10.1038\/s41586-025-09994-w (2026).","journal-title":"Nature"},{"key":"1426_CR182","doi-asserted-by":"publisher","first-page":"18022","DOI":"10.1021\/acs.jmedchem.4c01305","volume":"67","author":"X Zheng","year":"2024","unstructured":"Zheng, X. et al. Discovery of KT-474 \u2014 a potent, selective, and orally bioavailable IRAK4 degrader for the treatment of autoimmune diseases. J. Med. Chem. 67, 18022\u201318037 (2024).","journal-title":"J. Med. Chem."},{"key":"1426_CR183","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2025.105793","volume":"158","author":"LI Loberg","year":"2025","unstructured":"Loberg, L. I. et al. Nonclinical teratogenicity safety assessment of CRBN-engaging targeted protein degraders: Points to consider. Regul. Toxicol. Pharmacol. 158, 105793 (2025).","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"1426_CR184","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1021\/acschembio.4c00262","volume":"19","author":"TL Lynch","year":"2024","unstructured":"Lynch, T. L. et al. Quantitative measurement of rate of targeted protein degradation. ACS Chem. Biol. 19, 1604\u20131615 (2024).","journal-title":"ACS Chem. Biol."},{"key":"1426_CR185","doi-asserted-by":"publisher","first-page":"5524","DOI":"10.1021\/acs.jmedchem.2c01864","volume":"66","author":"Y Gao","year":"2023","unstructured":"Gao, Y. et al. Catalytic degraders effectively address kinase site mutations in EML4-ALK oncogenic fusions. J. Med. Chem. 66, 5524\u20135535 (2023).","journal-title":"J. Med. Chem."},{"key":"1426_CR186","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1021\/acschembio.2c00706","volume":"17","author":"Z Lin","year":"2022","unstructured":"Lin, Z., Shen, D., Yang, B. & Woo, C. M. Molecular and structural characterization of lenalidomide-mediated sequestration of eIF3i. ACS Chem. Biol. 17, 3229\u20133237 (2022).","journal-title":"ACS Chem. Biol."},{"key":"1426_CR187","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.3389\/fimmu.2018.02697","volume":"9","author":"SM Jensen","year":"2018","unstructured":"Jensen, S. M., Potts, G. K., Ready, D. B. & Patterson, M. J. Specific MHC-I peptides are induced using PROTACs. Front. Immunol. 9, 2697 (2018).","journal-title":"Front. Immunol."},{"key":"1426_CR188","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1021\/acschembio.7b00485","volume":"12","author":"P Ottis","year":"2017","unstructured":"Ottis, P. et al. Assessing different E3 ligases for small molecule induced protein ubiquitination and degradation. ACS Chem. Biol. 12, 2570\u20132578 (2017).","journal-title":"ACS Chem. Biol."},{"key":"1426_CR189","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.bbamcr.2004.10.004","volume":"1695","author":"P-M Kloetzel","year":"2004","unstructured":"Kloetzel, P.-M. The proteasome and MHC class I antigen processing. Biochim. Biophys. Acta Mol. Cell Res. 1695, 225\u2013233 (2004).","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"1426_CR190","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.3389\/fimmu.2017.01920","volume":"8","author":"SC Moser","year":"2017","unstructured":"Moser, S. C., Voerman, J. S. A., Buckley, D. L., Winter, G. E. & Schliehe, C. Acute pharmacologic degradation of a stable antigen enhances its direct presentation on MHC class I molecules. Front. Immunol. 8, 1920 (2017).","journal-title":"Front. Immunol."},{"key":"1426_CR191","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.1039\/D2CS00141A","volume":"51","author":"PS Dragovich","year":"2022","unstructured":"Dragovich, P. S. Degrader-antibody conjugates. Chem. Soc. Rev. 51, 3886\u20133897 (2022).","journal-title":"Chem. Soc. Rev."},{"key":"1426_CR192","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw7317","volume":"365","author":"S Naqvi","year":"2019","unstructured":"Naqvi, S. et al. Conservation, acquisition, and functional impact of sex-biased gene expression in mammals. Science 365, eaaw7317 (2019).","journal-title":"Science"}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01426-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01426-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01426-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:18:25Z","timestamp":1785518305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01426-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":192,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1426"],"URL":"https:\/\/doi.org\/10.1038\/s41573-026-01426-2","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"17 March 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.G., J.S. and R.R. are employees of ApconiX, an integrated drug safety and research laboratory consultancy. A.A., K.D. and A.R. are employees of Merck & Co, a company involved in developing TPDs. D.L.D. is an employee of Foghorn Therapeutics, a company involved in developing TPDs. M.E. is an employee of Novo Nordisk, a company involved in developing TPDs. R.R.H. is an employee of Amgen, a company involved in developing TPDs. L.H.J. is a is a co-founder of Anvia Therapeutics, an adviser to companies developing TPDs, and holds equity in Hyku Biosciences and Rapafusyn Pharmaceuticals. L.H.J. previously received funding from Deerfield at the Center for Protein Degradation at Dana Farber Cancer Institute. N.V. is an employee of The University of Aberdeen and holds patents on thalidomide analogues. T.S.L. is an employee of Takeda, a company involved in developing TPDs. L.I.L. is an employee of Abbvie, a company involved in developing TPDs. D.M. is an employee of Nurix Therapeutics, a company involved in developing TPDs. L.P.M. and R.O\u2019L. are employees of HESI, an organization that works with scientists from industry (including companies developing TPDs) to solve complex scientific issues. A.V. is an employee of Novartis, a company involved in developing TPDs. G.Y.-H. is an employee of Johnson & Johnson, a company involved in developing TPDs. M.P. is an employee of Bayer AG, a company involved in developing TPDs. Z.R. is director of TPD-focused drug discovery centre at the Institute of Cancer Research\u00a0and holds patents on cereblon-dependent degraders. N.K. is an employee of Boehringer Ingelheim, a company involved in developing TPDs. R.L.W. is an Employee of Aclairo Pharmaceutical Development Group, a company that provides scientific and regulatory advice to companies developing TPDs. T.P. holds a consulting contract and Incentive Units in Oerth Bio, an LLC that discovers and develops agricultural TPD compounds.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}